P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients

A meta-analysis of biomarkers for the prognosis of triple-negative breast cancer patients

(2016) Yu Gui et al.   Biomarkers in Medicine

MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy

(2016) Benjamin C. Calhoun et al.   BMC CANCER

Importance of hereditary and selected environmental risk factors in the etiology of inflammatory breast cancer: a case-comparison study

(2016) Roxana Moslehi et al.   BMC CANCER

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

(2016) Giampaolo Bianchini et al.   Nature Reviews Clinical Oncology

Identification of Prognostic Risk Factors for Transient and Persistent Lymphedema after Multimodal Treatment for Breast Cancer

(2016) Myungsoo Kim et al.   Cancer Research and Treatment

Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer

(2016) Ji-Yeon Kim et al.   Cancer Research and Treatment

p53 in the DNA-Damage-Repair Process

(2016) Ashley B. Williams et al.   Cold Spring Harbor Perspectives in Medicine

Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single-Institutional Series

(2016) Min-Young Lee et al.   PLoS One

Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients

(2015) Fausto Petrelli et al.   BREAST CANCER RESEARCH AND TREATMENT

Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study

(2015) Rumiko Tashima et al.   PLoS One

Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival

(2015) Se Kyung Lee et al.   PLoS One

Two Decades After BRCA: Setting Paradigms in Personalized Cancer Care and Prevention

(2014) F. J. Couch et al.   SCIENCE

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

(2013) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Distincttumor protein p53mutants in breast cancer subgroups

(2012) Anne Dumay et al.   INTERNATIONAL JOURNAL OF CANCER

Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse

(2011) J. Chuck Harrell et al.   BREAST CANCER RESEARCH AND TREATMENT

Management and treatment of triple-negative breast cancer patients from the NEMESI study: An Italian experience

(2011) V. Adamo et al.   EUROPEAN JOURNAL OF CANCER

p53 Status Identifies Two Subgroups of Triple-negative Breast Cancers with Distinct Biological Features

(2011) E. Biganzoli et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

(2011) M. Dowsett et al.   JNCI-Journal of the National Cancer Institute

Directed Therapy of Subtypes of Triple-Negative Breast Cancer

(2011) L. A. Carey   ONCOLOGIST

Triple-Negative Breast Cancer: An Unmet Medical Need

(2011) C. A. Hudis et al.   ONCOLOGIST

Breast Cancer Subtypes and the Risk of Local and Regional Relapse

(2010) K. David Voduc et al.   JOURNAL OF CLINICAL ONCOLOGY

Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates

(2010) Minoru Miyashita et al.   VIRCHOWS ARCHIV